Itolizumab gets DCGI nod for emergency use in treating COVID-19 patientsJuly 12, 2020 0 By FM
The Drugs Controller General of India (DCGI) has approved a monoclonal antibody injection itolizumab for restricted emergency use for the treatment of ‘cytokine’ release syndrome in moderate to severe acute respiratory distress syndrome patients due to COVID-19.
BIopharmaceutical company Biocon received the approval for using its itolizumab that has primarily been approved and used to treat psoriasis, a debilitating skin ailment.
Itolizumab is a humanised IgG1 monoclonal antibody. It selectively targets CD6, a T cell marker involved in co-stimulation, adhesion and maturation of T cells. The drug binds to CD6 to down-regulate T cell activation, causing a reduction in synthesis of pro-inflammatory cytokines. The drug’s ability to help alleviate the aggressive immune response of the body’s immune system was considered for administering the drug in severe cases of COVID-19.